Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.

Autor: Huynh JC; Hematology Oncology, University of California, Davis, Sacramento, CA 95817, USA., Schwab E; Hematology Oncology, University of California, Davis, Sacramento, CA 95817, USA., Ji J; Internal Medicine, University of California, Davis, Sacramento, CA 95817, USA., Kim E; Hematology Oncology, University of California, Davis, Sacramento, CA 95817, USA., Joseph A; Hematology Oncology, University of California, Davis, Sacramento, CA 95817, USA., Hendifar A; Hematology Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Cho M; Hematology Oncology, University of California, Davis, Sacramento, CA 95817, USA., Gong J; Hematology Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2020 May 06; Vol. 12 (5). Date of Electronic Publication: 2020 May 06.
DOI: 10.3390/cancers12051168
Abstrakt: The treatment of advanced gastrointestinal (GI) cancers has become increasingly molecularly driven. Molecular profiling for HER2 and PD-L1 status is standard for metastatic gastroesophageal (GEJ) cancers to predict benefits from trastuzumab (HER2-targeted therapy) and pembrolizumab (anti-PD-1 therapy), while extended RAS and BRAF testing is standard in metastatic colorectal cancer to predict benefits from epidermal growth factor receptor (EGFR)-targeted therapies. Mismatch repair (MMR) or microsatellite instability (MSI) testing is standard for all advanced GI cancers to predict benefits from pembrolizumab and in metastatic colorectal cancer, nivolumab with or without ipilimumab. Here we review recent seminal trials that have further advanced targeted therapies in these cancers including Poly (adenosine diphosphate-ribose) polymerases (PARP) inhibition in pancreas cancer, BRAF inhibition in colon cancer, and isocitrate dehydrogenase (IDH) and fibroblast growth factor receptor (FGFR) inhibition in biliary tract cancer. Targeted therapies in GI malignancies constitute an integral component of the treatment paradigm in these advanced cancers and have widely established the need for standard molecular profiling to identify candidates.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje